Top News

JJ Beats Q4 Profit Expectations, but Misses on Revenue

Johnson & Johnson’s quarterly revenue didn’t meet market expectations, whereas exceeded Q4 profit results, according to Wednesday’s report.

j&j profit surpasses expectationsPhoto: Reuters

Sales of the anticancer medicine Imbruvica and the drug for the treatment of psoriasis Stelara fell short of expectations.

Johnson & Johnson pharmaceutical division revenue grew by 3.5 percent to touch $10.55 billion in Q4, whereas the average forecast of two analysts surveyed by Reuters was of $10.63 billion.

The company is expecting adjusted earnings in 2020 of $8.95- $9.10 per share, with revenue in the range of $85.4 billion to $86.2 billion.

Meantime, J&J quarterly profit grew from $3.04 billion, or $1.12 per share to $4.01 billion, or $1.50 per share at annual rate.

Excluding some costs, J&J earned $1.88 per share – one cent higher than analysts estimated, according to IBES from Refinitiv.

Total amount of sales grew by 1.7 percent to $20.75 billion, which is also below the markets’ average forecast of $20.80 billion.

Johnson & Johnson shares declined by 0.97 percent at 1556 GMT.

Source: Reuters


Leave a Reply

Your email address will not be published. Required fields are marked *